Adaptive and maladaptive roles of different angiotensin receptors in the development of cardiac hypertrophy and heart failure

被引:4
|
作者
Bhullar, Sukhwinder K.
Dhalla, Naranjan S. [1 ]
机构
[1] Univ Manitoba, St Boniface Hosp, Inst Cardiovasc Sci, Albrechtsen Res Ctr, Winnipeg, MB, Canada
关键词
angiotensin II; angiotensin II receptors; adaptive cardiac hypertrophy; maladaptive cardiac hypertrophy; heart failure; II TYPE-2 RECEPTOR; LEFT-VENTRICULAR HYPERTROPHY; ROSTRAL VENTROLATERAL MEDULLA; CONVERTING ENZYME-INHIBITORS; SYMPATHETIC AFFERENT REFLEX; VASCULAR SMOOTH-MUSCLE; OXIDATIVE STRESS; BLOOD-PRESSURE; AT(1) RECEPTOR; AT(2) RECEPTORS;
D O I
10.1139/cjpp-2023-0226
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Angiotensin II (Ang II) is formed by the action of angiotensin-converting enzyme (ACE) in the renin-angiotensin system. This hormone is known to induce cardiac hypertrophy and heart failure and its actions are mediated by the interaction of both pro-and antihypertrophic Ang II receptors (AT1R and AT2R). Ang II is also metabolized by ACE 2 to Ang-(1-7), which elicits the activation of Mas receptors (MasR) for inducing antihypertrophic actions. Since heart failure under different pathophysiological situations is preceded by adaptive and maladaptive cardiac hypertrophy, we have reviewed the existing literature to gain some information regarding the roles of AT1R, AT2R, and MasR in both acute and chronic conditions of cardiac hypertrophy. It appears that the activation of AT1R may be involved in the development of adaptive and maladaptive cardiac hypertrophy as well as subsequent heart failure because both ACE inhibitors and AT1R antagonists exert beneficial effects. On the other hand, the activation of both AT2R and MasR may prevent the occurrence of maladaptive cardiac hypertrophy and delay the progression of heart failure, and thus therapy with different activators of these antihypertrophic receptors under chronic pathological stages may prove beneficial. Accordingly, it is suggested that a great deal of effort should be made to develop appropriate activators of both AT2R and MasR for the treatment of heart failure subjects.
引用
收藏
页码:86 / 104
页数:19
相关论文
共 50 条
  • [1] Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development
    Caturano, Alfredo
    Vetrano, Erica
    Galiero, Raffaele
    Salvatore, Teresa
    Docimo, Giovanni
    Epifani, Raffaella
    Alfano, Maria
    Sardu, Celestino
    Marfella, Raffaele
    Rinaldi, Luca
    Sasso, Ferdinando Carlo
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2022, 23 (05)
  • [2] Angiogenesis and Cardiac Hypertrophy Maintenance of Cardiac Function and Causative Roles in Heart Failure
    Oka, Toru
    Akazawa, Hiroshi
    Naito, Atsuhiko T.
    Komuro, Issei
    CIRCULATION RESEARCH, 2014, 114 (03) : 565 - 571
  • [3] Protective Effects of Thyroid Hormone Deprivation on Progression of Maladaptive Cardiac Hypertrophy and Heart Failure
    Kerp, Helena
    Hoenes, Georg Sebastian
    Tolstik, Elen
    Hoenes-Wendland, Judith
    Gassen, Janina
    Moeller, Lars Christian
    Lorenz, Kristina
    Fuehrer, Dagmar
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [4] Heart failure and cardiac hypertrophy
    Rame J.E.
    Dries D.L.
    Current Treatment Options in Cardiovascular Medicine, 2007, 9 (4) : 289 - 301
  • [5] Brain renin-angiotensin system in hypertension, cardiac hypertrophy, and heart failure
    Campos, Luciana Aparecida
    Bader, Michael
    Baltatu, Ovidiu Constantin
    FRONTIERS IN PHYSIOLOGY, 2012, 2
  • [6] Roles of histone acetylation sites in cardiac hypertrophy and heart failure
    Funamoto, Masafumi
    Imanishi, Masaki
    Tsuchiya, Koichiro
    Ikeda, Yasumasa
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [7] Alterations in mitochondrial function in cardiac hypertrophy and heart failure
    Osterholt, Moritz
    Nguyen, T. Dung
    Schwarzer, Michael
    Doenst, Torsten
    HEART FAILURE REVIEWS, 2013, 18 (05) : 645 - 656
  • [8] Role of angiotensin II in hypertension-induced cardiac hypertrophy and failure
    Csikós T.
    Chung O.
    Unger T.
    Heart Failure Reviews, 1999, 3 (3) : 159 - 168
  • [9] Targeting Cardiac Hypertrophy: Toward a Causal Heart Failure Therapy
    Bisping, Egbert
    Wakula, Paulina
    Poteser, Michael
    Heinzel, Frank R.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2014, 64 (04) : 293 - 305
  • [10] Status of β1-Adrenoceptor Signal Transduction System in Cardiac Hypertrophy and Heart Failure
    Dhalla, Naranjan S.
    Bhullar, Sukhwinder K.
    Adameova, Adriana
    Mota, Karina Oliveira
    de Vasconcelos, Carla Maria Lins
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2023, 24 (09)